M&A Deal Summary |
|
|---|---|
| Date | 2019-02-05 |
| Target | Melinta Therapeutics - Fusidic Acid |
| Sector | Life Science |
| Buyer(s) | Arrevus |
| Sellers(s) | Melinta Therapeutics |
| Deal Type | Divestiture |
SEARCH BY
Arrevus is a biotechnology company whose mission is to eliminate the threat of antibiotic resistance and improve treatment outcomes for serious infectious diseases. The company is applying evolutionary templates to develop first-in-class proprietary anti-infectives known as Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs). Arrevus was formed in 2015 and is based in Durham, North Carolina.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Connecticut M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2019 M&A | 1 of 1 |
Melinta Therapeutics is a molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. Melinta Therapeutics is based in New Haven, Connecticut.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Connecticut M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2019 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-11-29 |
The Medicines Company - Infectious Disease Business
Parsippany, New Jersey, United States The Medicines Company - Infectious Disease Business includes three marketed products: recently approved and launched Vabomere (vaborbactam/meropenem), and established commercial products Orbactiv (oritavancin) and Minocin IV (minocycline). |
Buy | $270M |
